روند روزانه سهام شرکت
Acceleron Pharma Inc.
این نمودار بصورت روزانه به روز رسانی می گردد
|نام شرکت||نماد||سرمایه (میلیون دلار)||کشور||عرضه اولیه||زیر مجموعه|
|Acceleron Pharma Inc.||XLRN||۱۲۴۰||United States||۲۰۱۳||Biotechnology
Biological Products-No Diagnostic Substances
We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases. Our research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta, or TGF-beta, protein superfamily. By combining our discovery and development expertise, including our proprietary knowledge of the TGF-beta superfamily, and our internal protein engineering and manufacturing capabilities, we have built a highly productive discovery and development platform that has generated innovative therapeutic candidates with novel mechanisms of action. These differentiated therapeutic candidates have the potential to significantly improve clinical outcomes for patients across many fields of medicine. We have four internally discovered therapeutic candidates that are currently in clinical trials: luspatercept, sotatercept, dalantercept and ACE-083.